 Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 12 | 1 | 13 | | 1996 | 9 | 2 | 11 | | 1997 | 10 | 2 | 12 | | 1998 | 14 | 1 | 15 | | 1999 | 5 | 2 | 7 | | 2000 | 7 | 1 | 8 | | 2001 | 15 | 1 | 16 | | 2002 | 8 | 2 | 10 | | 2003 | 8 | 8 | 16 | | 2004 | 16 | 5 | 21 | | 2005 | 9 | 6 | 15 | | 2006 | 20 | 6 | 26 | | 2007 | 15 | 6 | 21 | | 2008 | 21 | 10 | 31 | | 2009 | 14 | 9 | 23 | | 2010 | 20 | 15 | 35 | | 2011 | 26 | 9 | 35 | | 2012 | 24 | 11 | 35 | | 2013 | 31 | 15 | 46 | | 2014 | 38 | 16 | 54 | | 2015 | 35 | 15 | 50 | | 2016 | 34 | 21 | 55 | | 2017 | 35 | 18 | 53 | | 2018 | 42 | 15 | 57 | | 2019 | 52 | 22 | 74 | | 2020 | 51 | 17 | 68 | | 2021 | 35 | 33 | 68 | | 2022 | 8 | 44 | 52 | | 2023 | 0 | 64 | 64 | | 2024 | 42 | 36 | 78 | | 2025 | 42 | 7 | 49 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Baird RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, Moreno I, Oliveira M, Armstrong A, Turner N, Incorvati J, Twelves C, Ciruelos E, Hamilton E, Patel MR, Kabos P, Ciardullo C, Klinowska T, Lindemann JPO, Mathewson AM, Morrow CJ, Sykes A, Yang J, Zhang B, Victoria I. Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1. Clin Cancer Res. 2025 Oct 15; 31(20):4244-4254.
-
Wesolowski R, Rugo HS, Specht JM, Han HS, Kabos P, Vaishampayan U, Wander SA, Gogineni K, Spira A, Schott AF, Abu-Khalaf M, Mutka SC, Suzuki S, Sullivan B, Gorbatchevsky I, Layman RM. Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Clin Cancer Res. 2025 Oct 01; 31(19):4040-4048.
-
Cohen DJ, Goldberg JD, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott AJ, Bekaii-Saab T, Messersmith WA, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. Oncologist. 2025 Oct 01; 30(10).
-
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025 Sep 11; 146(11):1276-1285.
-
Wang SM, Dexter J, Wolsky R, Lefkowits C. Management of Advanced Stage Endometrial Cancer With Non-Measurable Disease After Surgery. Curr Treat Options Oncol. 2025 Sep; 26(9):820-828.
-
Lentz RW, Hu J, Robinson H, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Messersmith WA, Lieu CH. Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025 Aug; 23(8).
-
Milhem MM, Wise-Draper TM, Chandra S, Hanna GJ, Laux DE, Medina TM, Ansstas G, Daud A, Kelly CM, O'Day SJ, Perez CA, Wong MK, Friedlander PA, Kristedja TS, Burgess MA, Cowey CL, Hanks BA, Weight RM, Daniel WL, Feltner DE, Mix S, Sindelar L, Bexon AS, Bexon MF, Michel RE, Bhatia S. Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors. J Immunother Cancer. 2025 Jul 25; 13(7).
-
Groisser A, Frantz A, Geller JI, Ortiz MV, Walterhouse D, Ranalli M, Woods-Swafford W, Schoettler P, Garrington T, Mullen EA, Ash S, Bardhan P, Balis F, Dome JS. Anti-Tumor Activity of Paclitaxel-Containing Regimens in Recurrent/Refractory Wilms Tumor. Pediatr Blood Cancer. 2025 Oct; 72(10):e31915.
-
Siontis BL, Rice JD, Schuetze SM, Rottmann D, Angeles CV, Fox AK, Zyczynski LE, Hayek S, Robinson SI, Okuno SH, Ho TP, Chugh R. A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma. Clin Cancer Res. 2025 Jul 15; 31(14):2919-2925.
-
Wilky BA, Julian KA, Maleddu A, Mailhot AC, Cartwright CR, Gao D, Moreno Tellez C, Kemp LE, Therrien NR, Chaudhry SS, Rytlewski JD, Brockman QR, Davila E, Elias AD. A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas. Clin Cancer Res. 2025 Jul 15; 31(14):2945-2956.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|